Brainomix will be unveiling a series of new studies this week at the International Stroke Conference (ISC; 5–7 February, Los Angeles, USA), further validating the impact of its Brainomix 360 system to “transform” stroke treatment rates for patients across care networks. A press release notes that the latest research—conducted with some of the world’s leading academic stroke institutions—also reflects the company’s focus on exploring breakthrough advances in artificial intelligence (AI) imaging for stroke.
“We have had a longstanding academic partnership with Brainomix, harnessing their cutting-edge AI algorithms to explore some exciting scientific frontiers,” said Waleed Brinjikji (Mayo Clinic, Rochester, USA). “These latest studies have yielded fascinating insights around eloquence and brain frailty, revealing a more nuanced understanding of stroke, and informing potentially novel approaches to patient selection for stroke treatment.”
Brainomix 360 is a comprehensive, fully US Food and Drug Administration (FDA)-cleared platform powered by “the most advanced and clinically validated AI algorithms built around basic imaging”—most notably through the company’s flagship e-ASPECTS module. The patented, explainable AI tool assesses non-contrast computed tomography (CT) scans to automatically generate an Alberta stroke programme early CT score (ASPECTS) and features a unique heatmap that enables a more nuanced assessment of each region.
Results from the largest real-world evaluation of stroke AI, involving data from more than 71,000 individual patients across 26 hospitals over a three-year period, will be presented on 5 February at ISC 2025. According to Brainomix, the findings show that sites utilising Brainomix 360 doubled their thrombectomy rates over the evaluation period, increasing an additional 37% compared with non-evaluation sites, while also achieving a faster door-in-door-out (DIDO) time by 65 minutes.
“The results from this large-scale study are unmatched in the field, robustly validating the power of Brainomix 360 to improve stroke care, enabling more patients to receive life-changing treatment,” stated George Harston, chief medical and innovation officer at Brainomix. “We are now seeing similarly impactful results from US stroke networks. Data from the Mayo Clinic will be presented on Thursday [6 February] at ISC, where using Brainomix 360 across the telestroke network was associated with more stroke thrombolysis being given, which was attributed to improved speed and confidence in decision-making.”
Results from the aforementioned evaluation of Brainomix 360 across the 17-site, multi-state Mayo Clinic telestroke network in the USA—involving more than 900 stroke patients—show greater rates of thrombolysis, as well as faster treatment decisions for both thrombolysis and thrombectomy when comparing the pre- and post-implementation phases.
The study investigators conclude: “This service evaluation highlighted the opportunity to improve efficiency of decision-making, even in the setting of a well-developed telestroke system. The impact was underpinned by the improved speed and confidence of imaging interpretation reflected in an offline simulation and qualitative feedback.”
Additional Brainomix presentations and posters set to be showcased at ISC this week include abstracts titled, ‘How dark is too dark? A multicentric retrospective study exploring the role of net water uptake in predicting futile recanalisation following mechanical thrombectomy’, ‘Brain frailty location is an independent predictor of functional outcome in patients undergoing recanalisation treatment for large vessel occlusion stroke’, and ‘Using CTP [CT perfusion]-based disconnectome mapping to identify optimal candidates for endovascular treatment in acute ischaemic stroke’.
